Abstract. Genomic and radiomic imaging profiles of invasive breast carcinomas from The Cancer Genome Atlas and The Cancer Imaging Archive were integrated and a comprehensive analysis was conducted to predict clinical outcomes using the radiogenomic features. Variable selection via LASSO and logistic regression were used to select the most-predictive radiogenomic features for the clinical phenotypes, including pathological stage, lymph node metastasis, and status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Cross-validation with receiver operating characteristic (ROC) analysis was performed and the area under the ROC curve (AUC) was employed as the prediction metric. Higher AUCs were obtained in the prediction of pathological stage, ER, and PR status than for lymph node metastasis and HER2 status. Overall, the prediction performances by genomics alone, radiomics alone, and combined radiogenomics features showed statistically significant correlations with clinical outcomes; however, improvement on the prediction performance by combining genomics and radiomics data was not found to be statistically significant, most likely due to the small sample size of 91 cancer cases with 38 radiomic features and 144 genomic features. © 2015 Society of Photo-Optical Instrumentation Engineers (SPIE)
Introduction
Radiogenomics integrates genomic and radiomic imaging profiles and has become an increasingly important research direction, especially in cancer, due to its potential to improve disease diagnosis, prognosis, and treatment choice.
1,2 Radiological imaging uses noninvasive procedures, such as x-ray computed tomography and magnetic resonance imaging (MRI), to assess the phenotype characteristics of tumor and such imaging is routinely used in clinical practice. 3, 4 Genomic profiling of tumor is usually obtained through invasive procedures, such as biopsy and surgery, providing direct observation on the molecular underpinnings of the tumor. The integration of these two different data modalities provides opportunities to investigate whether combining radiomics and genomics can achieve better prediction of tumor clinical types than using either alone.
Many clinical outcomes in oncology are closely related to cancer diagnosis, prognosis, and treatment planning. For invasive breast carcinoma, pathological stage and molecular receptor status are important variables considered in clinical practice. Pathological stage is based on the T-N-M classification of tumors. 5 T stage describes the size of the primary tumor and its invasion into the surrounding tissue; N stage evaluates the involvement of nearby lymph nodes; and M stage indicates distant metastasis of cancer. An overall pathological stage based on T, N, and M classifications is summarized for each cancer case. For the molecular receptor status of a patient, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are usually considered, 6 and treatments specific to the status of these receptors have been developed. For example, trastuzumab and lapatinib are quite effective for treating HER2+ breast cancer patients. 7 In summary, these clinical variables can stratify breast cancer patients into subgroups, with different disease severities, mechanisms, and treatment schemes.
Most of the existing research that integrates genomic data with radiomic imaging data are conducted to elucidate the correlations between genomic features and imaging features, as the latter is noninvasive and more inclusive of the entire tumor than the former. 1, [8] [9] [10] In this study, we explore the relationship between integrative radiogenomic features and several important clinical variables including pathology stage, lymph node metastasis, and molecular receptor stats. Innovatively, we assess whether combining genomic and radiomic features can improve the prediction of clinical outcomes. Radiomic features and genomic features are two distinct types of measurements of tumor. Radiomic features are closely related to tumor phenotypes, while genomic features characterize the underlying genetic and molecular profile of a tumor. Each of the two feature types can be used for possible determination or prediction of tumor characteristics and progression. By combining the two different feature types, more accurate and complete understanding of a tumor might be achieved than when using each of them alone. Such improved understanding may further help improve disease diagnosis and prognosis, thus facilitating better clinical decisions on patient care.
We analyzed a unique radiogenomic dataset consisting of 91 breast cancer patients. In particular, we extracted genomic data and radiomic images of 91 patients from The Cancer Genome Atlas (TCGA) 11 and The Cancer Imaging Archive (TCIA) 12 projects of the U.S. National Cancer Institute, respectively. Two kinds of statistical analyses were performed. First, t tests were used to learn the relationship between clinical outcomes and individual radiogenomic features. Second, we used logistic regression with LASSO regularization 13 to select genomic features and radiomic features predictive of clinical outcomes and to assess their prediction power.
Materials and Methods

Clinical Data
There were a total of 91 invasive breast carcinomas with both radiomic imaging profiles from TCIA and genomic data from TCGA. Clinical information of the 91 cases was downloaded from TCGA using TCGA-Assembler. 14 All samples were primary tumors from female patients. The patients' average age was 53.6 years with a standard deviation of 11.5 years and a range of 29 to 82 years with a median of 53 years. Out of the 91 invasive breast cancer cases, 87% (79/91) were ductal carcinoma, 11% (10/91) were lobular carcinoma, and 2% (2/91) were mixed. Only one patient was listed as having death as an outcome.
Patient ER status is a binary response, with 77 patients being ER+ and 14 patients being ER−. Regarding PR status, 72 patients are PR+ and 19 patients are PR−. HER2 status was missing, equivocal, positive, and negative in 6, 22, 14, and 49 patients, respectively. Only the HER2+ and HER2− samples were used in the analysis. We studied the prediction of ER, PR, and HER2 status of patients using radiomic features alone, genomic features alone, and the combination of both types of features. All genomic features of the ERBB2 gene were excluded from the analysis of predicting HER2 status because ERBB2 and HER2 are two aliases of the same gene. Therefore, we excluded ERBB2 features to avoid adding obvious confounders to the predictive models.
We also studied the discrimination between 22 stage I tumors and 11 stage III tumors, since stage I and stage III represent lessaggressive and more-aggressive tumors, respectively. For the prediction of lymph node metastasis, one patient sample was excluded from the analysis, because the number of lymph nodes with metastasis was missing in it. We dichotomized the samples into two classes, which are with and without lymph node metastasis, and the numbers of patients belonging to each class were 42 and 48, respectively.
Imaging Data and Radiomic Features
Dynamic contrast enhanced (DCE) MRI data of the 91 tumors were downloaded from TCIA. There were 108 MRI examinations available at the time of this study. In order to reduce the image acquisition variation, only the breast MRIs acquired on a GE scanner with 1.5 T magnet strength were analyzed (i.e., 93 cases). In addition, one case with missing images in the dynamic sequence and one case without genomic data were excluded from the study. The resulting 91 cases in the final dataset had been contributed by four institutions with examination dates ranging from 1999 to 2004.
MR images used in this study had been acquired with a standard double breast coil on a 1.5 T GE whole-body MRI system. Only T1-weighted DCE MRIs were used for the study. The imaging protocols included one pre-and three to five postcontrast images obtained using a T1-weighted three-dimensional spoiled gradient echo sequence with a gadolinium-based contrast agent.
Each MRI exam was independently reviewed by three experienced TCIA breast radiologists blinded to the outcome data. The primary tumor location on MRI was determined by consensus using the radiologists' annotated information on the images. This tumor location information was the only input for the quantitative image analysis of the breast tumor on MRI. Prior to the computer extraction of the various image phenotypes, the tumor was segmented on the MRI using the radiologist-indicated tumor center and a computational fuzzy c-means algorithm. 15 Quantitative radiomics analysis was then conducted, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 27 yielding 38 radiomic features characterizing the size, shape, morphology, enhancement texture, kinetics, and variance kinetics of each tumor. These radiomic features can be sorted into six MRI phenotype categories: (1) size, giving the tumor dimensions, such as volume and surface area, (2) shape, characterizing the tumor geometry, such as sphericity and irregularity, (3) morphology, combining tumor shape and margin characteristics, such as spiculation and margin sharpness, (4) enhancement texture, characterizing tumor textural properties based on the gray-level co-occurrence matrix, such as energy, entropy, and contrast, (5) kinetic curve assessment, characterizing the physiological process of the uptake and washout nature of the contrast agent in a breast tumor during the dynamic imaging series, such as uptake rate, washout rate, and signal enhancement ratio, and (6) enhancement-variance kinetic features, characterizing the time course of the spatial variance of the enhancement within a breast tumor, such as variance increase rate and variance decrease rate. Information about the radiomic features, including feature name, label, description, and category, is listed in Table 1 . Figure 1 shows the images of two tumor cases with the information of some clinical variables and the values of some radiomic features.
Genomic Data
Genes were selected based on two recently published papers 28, 29 which explored genes involved in breast cancer. These two papers discussed genes that are expected to influence the germination and progress of breast cancer. Genomic data of these genes in the 91 tumors were downloaded from TCGA using TCGA-Assembler 14 to obtain three types of genomic features: copy number (CN), gene expression (GE), and DNA methylation (ME). Protein expressions were not considered as they were missing in a large portion of the samples. More explanations of CN, GE, and ME features are included in the Appendix. For gene expression data, we used the normalized read counts of RNA-seq data, which were generated by TCGA using the Illumina HiSeq 2000 system and processed using the MapSplice genome alignment algorithm 30 and the RSEM gene expression estimation algorithm. 31 TCGA used the Affymetrix Genome-Wide Human SNP Array 6.0 and the circular binary segmentation algorithm 32 to obtain gene CNs. ME was measured using Infinium HumanMethylation450 BeadChip. For CN, GE, and ME, TCGA did not have all three features for every sample. Twenty-six features did not have measurements in 29 patients, which were nearly one third of the patients. Thus, these features were removed from analysis. One patient did not have data for four methylation features, including PTEN(ME), TP53(ME), AFF2(ME), and ATM(ME). These missing values were imputed using the sample mean of the feature across other patients whose data were present.
In the end, a genomic dataset was obtained with 144 genomic features for 70 genes, including 70 gene expression features, 70 CN features, and 4 methylation features. The full list of genes and their genomic features used in the analysis are listed in Table 5 . A gene-level CN was calculated for each gene and each sample using TCGA-Assembler. The methylation value of a gene is the average methylation level of CpG sites that are DNAse hypersensitive and are within 1500 base-pairs upstream of the transcription start site of the gene.
Statistical Methods
All genomic and radiomic imaging features were standardized to have mean 0 and standard deviation 1 prior to the subsequent analyses. Two types of statistical tests were conducted on the radiogenomic data.
First, t test was employed to investigate the differences of mean values in the different subgroups of patients as defined by the clinical outcomes. The Benjamini-Hochberg procedure 33 was used to control the false discovery rate (FDR) for the tests of each clinical outcome with all radiomic features or all genomic features. Adjusted p-values no larger than 0.1 were considered significant. Second, logistic regression was used to model the relationship between clinical outcomes and radiogenomic features. The number of regressors (indicated by P) is relatively large, i.e., P ¼ 38 for radiomic imaging data and P ¼ 144 for genomic data. Logistic regression was conducted with LASSO regularization 13 as the variable selection method to identify the features that best predict clinical outcomes. The LASSO method is a shrinkage and variable selection method for regression models. It maximizes a penalized log-likelihood function, which can be transformed into the following optimization problem given a positive value of λ: E Q -T A R G E T ; t e m p : i n t r a l i n k -; s e c 2 . 4 ; 6 3 ; 1 5 4 argmax
where y i is a {0, 1} indicator for the clinical phenotype of patient i, β 0 is the intercept in the logistic model, β is the coefficient vector in logistic regression, x i denotes the radiomic profile or genomic profile of patient i, and λ is the tuning parameter determining the number of nonzero coefficients. After optimization, only salient features contributing to the discrimination between different clinical phenotypes will have nonzero β coefficients. Genomic features and radiomic features were investigated separately and combined in the logistic regression with LASSO regularization in order to select the best genomic predictors, the best radiomic predictors, and the best predictors among all radiogenomic features. In addition, the area under the receiver operating characteristic (ROC) curve (AUC) was obtained under cross-validation and is reported as the performance metric for prediction accuracy. Because LASSO requires tuning of the model parameter λ, which controls the strength of regularization, a two-tier crossvalidation was implemented to ensure the high quality of model training and to evaluate the generalization prediction performance, as illustrated in Fig. 2 . The inner-tier cross-validation was used to select the best λ value with the highest AUC on the testing data in the inner-tier cross-validation, and the outer-tier cross-validation measured the generalization performance of the prediction scheme. For each clinical outcome, the same number of data folds was used for both inner-tier cross-validation and outer-tier cross-validation. Since some of the clinical phenotypes were quite unbalanced (e.g., 77 ER+ versus 14 ER−), when splitting the data into training and testing sets, the percentage of samples with a given phenotype was kept the same in both training and testing sets as in the original whole dataset. Combine n-1 data folds as the training set T.
Use the remaining data fold as the testing set S.
Generate a sequence of candidate values for the tuning parameter .
Split T into n inner-tier data folds.
Combine n-1 inner-tier data folds as the inner-tier training set T t .
Use the remaining innertier data fold as the inner-tier testing set T s .
Apply logistic regression with LASSO regularization on the set T t under each value.
Test the trained model on T s , and obtain inner-tier AUCs for prediction under different values.
Select the value with the largest mean of inner-tier AUCs.
Apply logistic regression with LASSO regularization on T under the selected value.
Test the trained model on S, and obtain the out-tier AUC for prediction of S.
Repeat p times.
Repeat q times. two-tier cross-validation scheme. The numbers of data folds and total cross-validation trials used for each clinical outcome are listed in Table 2 .
We consider the AUC of each cross-validation trial as a sample from the AUC distribution and present the mean (mean AUC ) and standard deviation (sd AUC ) of sampled AUCs in Table 3 .
We used R to carry out the analysis. R package "glmnet" was used for LASSO analysis and R package "pROC" was used for ROC analysis.We have provided a formal workflow tool for the radiogenomic analysis in our paper. 34 Figure 3 shows the radiomic features whose mean values significantly (adjusted p-value ≤ 0.1) changed between clinical types as evaluated by t tests. Statistically significant associations are represented by edges. If ER+, PR+, HER2+, stage III, and positive lymph node metastasis are defined as the higher classes for the corresponding clinical outcome, a red edge means that the radiomic feature has a significantly larger mean value in the higher class than in the lower class, while a blue edge means the opposite. Note that all tumor size features (S category in Fig. 3 ) are significantly positively associated with tumor stage, showing that tumor size is one of the major factors considered in the current tumor staging system. Tumor shape feature G2 (irregularity) is significantly positively associated with tumor stage, indicating that higher-stage tumors have more irregular shape. One tumor margin feature M3 (variance of radial gradient histogram) and two enhancement texture features T7 (inverse difference moment) and T11 (sum average) are also predictive of tumor stage. Enhancement texture T5 (angular second momentenergy) is predictive of PR status. No radiomic feature is significantly associated with other clinical outcomes, including lymph node metastasis, ER, and HER2 status. Please check Table 1 for the category label and index of radiomic features.
Results
Using t tests, we also identify the genomic features with significantly differential mean values between high and low classes of clinical outcomes (see Table 4 ). There is no genomic feature that significantly (adjusted p-value ≤ 0.1) differentiates phenotypes of tumor stage and lymph node metastasis. A lot of genomic features are significantly associated with ER and PR status, and only one genomic feature, TP53(ME), is significantly associated with HER2 status.
Results of LASSO-based logistic regression analysis are given in Table 3 . Genomic features performed better than radiomic features in predicting ER and PR status, with average AUCs of 0.916 and 0.775 from cross-validations, respectively, while radiomic features performed better in predicting pathological stage with an average AUC of 0.877. These results were expected as ER and PR statuses are genomic types closely related to tumor genomic profiles while pathological stage is clinically defined on phenotypes of the tumors, some of which can be directly characterized by imaging. For prediction of lymph node metastasis and HER2 status, neither genomic features nor radiomic imaging features did well (with average AUCs ≤ 0.7). The most discriminative radiomic feature to predict less-aggressive stage I tumors versus more-aggressive stage III tumors was effective diameter, which measures the tumor size. Larger values of effective diameter are usually an important sign of more-aggressive tumors. 35 Our results agree with this observation, as the coefficient of effective diameter in the logistic prediction model, which is trained based on effective diameter alone and all tumor samples for predicting tumor pathological stage, is positive. The most discriminative genomic feature to predict tumor ER status is AURKB(GE), and its coefficient in the logistic model trained based on AURKB(GE) alone and all tumor samples for predicting ER status is negative.
Comparison of AUCs obtained on the integrated radiogenomics data with those obtained on genomic data or radiomic data alone indicated no improvement in the prediction accuracy by combining two different data modalities. For the case of pathological stage, ER, and PR status, the reason could be that no feature from the less-predictive data modality can provide a complementary prediction power to the most-predictive features from the more-predictive data modality. Both the most frequently selected feature set and the most frequently selected individual features do not change or change very little between the more-predictive data modality and the integrated data. For lymph node metastasis and HER2 status, it seems that both genomic data and radiomic data lack the power for a good prediction and their integration did not show any improvement.
Discussion
A comprehensive analysis was conducted on the integration of genomic and radiomic data of 91 breast cancer patients from TCGA and TCIA. We believe that our study is the largest study to date that combines multiple types of genomic data with radiomic data in predicting breast cancer prognosis. Relationships were explored between the genomic and radiomic features and five selected clinical outcomes categorized the tumors into different subgroups related to prognosis and treatment scheme.
The single variable t test identified that all tumor size features are significantly associated with the tumor pathological stage showing the importance of size in the stage classification of tumors. However, no individual radiomic feature was found Table 2 The numbers of data folds and cross-validation trials used in the two-tier cross-validation. ≥ 0.5 PAK1(GE), TP53(ME), MYC(GE), PIK3CA(CN), CCND3(GE), PTPN22(GE), AFF2(ME), PTEN(ME),
MTHFD1L(GE), CTCF(GE), CCND3(CN), ZNF703 (GE), PPP2R1A(GE), PTEN(GE), PPP2R2A(GE), CHEK1(CN), ERBB2(CN), MTAP(CN), PPP2R2B (GE), GATA3(CN), RB1(GE)
Irregularity, inverse difference moment, variance of radial gradient histogram, variance of margin sharpness Irregularity, MYC(GE), inverse difference moment, PAK1(GE), AFF2(ME), ERBB2(CN), CTCF(GE), sum average, CCND3(GE), TP53(ME), variance of margin sharpness, PPP2R2B(GE), CCND3(GE), MTHFD1L(GE), PTEN(ME), CCND3(CN), PIK3CA
(CN), GATA3(GE), ERBB2(GE), PTPN22(GE)
Journal Note: CN, copy number; GE, gene expression; ME, DNA methylation.
to be significantly associated with lymph node metastasis, ER, and HER2 status. On the other hand, no individual genomic feature showed significant association with tumor stage and lymph node metastasis. We found many more genomic features significantly associated with ER and PR status than with HER2 status.
Using logistic regression with LASSO regularization, the effective diameter was selected as the most-predictive feature for tumor pathological stage, outperforming the genomic features in this clinical task as expected given the connection between the current tumor staging classification and tumor size. Genomic feature AURKB(GE) was selected as the mostpredictive feature of ER status. Genomic features outperformed radiomic features in predicting both ER status and PR status, both of which are molecular characteristics.
We observed that radiomic features were more predictive for tumor stage than lymph node involvement. Note that the current tumor staging system is based on the T-N-M status of the tumor. Tumor T status describes the size of the original (primary) tumor and whether the tumor has invaded nearby tissue, which has an important role in tumor staging and can be characterized by MRI. It is not surprising to see that radiomic features have a high AUC for predicting tumor stage due to the correlation between tumor T status and tumor stage. However, lymph node involvement, i.e., the tumor N status, may not be easily characterized by MRI of the primary tumor, since it does not account for or analyze the number of positive lymph nodes. Thus, radiomic features cannot provide a good prediction of lymph node involvement.
Overall, the prediction performance by genomic features alone, radiomic features alone, and combined radiogenomics features showed significant correlations with clinical outcomes. However, the change in predictive performance when going from either genomic features alone or radiomic features alone to the combined radiogenomic features was not found to be statistically significant, most likely due to the limited data size (91 cancer cases with 38 radiomic features and 144 genomic features) and the types of clinical variables that we considered. Tumor stage is a phenotypic variable closely related to tumor size and invasion characterized by MRI. Thus, radiomic features alone already provided a good prediction. Compared to radiomic features, genomic features may have a weaker correlation with tumor stage and, thus, did not add additional prediction power. On the other hand, for clinical variables related to the genomic status of a tumor, such as ER status and PR status, it was not surprising to find that genomic features have more predictive power, while radiomic features do not provide additional predictive power. However, for other types of clinical variables, such as survival, there is the potential for combined genomic and radiomic features to provide a better prediction than each type of feature alone, although, unfortunately, on our limited data with only one terminal event, we could not assess this.
In the future, we plan to collect more tumor samples to study in depth whether combining radiomic and genomic features would improve the prediction of clinical profiles. Currently, the clinical outcomes are taken as binary variables, but some of them actually have multiple outcome values, for example, the tumor pathological stage. In the future work, we will use multinomial regression for the analysis of these clinical variables. Also, we will consider the dependence among features when doing feature selection and prediction to coincide with the collinearity among features.
Balancing techniques are useful when data are imbalanced and the precision and recall are of different importance. In our analysis, since the ROC curve (and hence AUC) is insensitive to changes in class imbalance, 21 we did not make use of balancing techniques in the analysis. Besides, if balancing techniques were utilized, we would have to reinterpret the AUC because of the trade-off between the precision and recall induced by using balancing techniques, such as SMOTE. 36 These can be considered in future work if a trade-off between the precision and recall is necessary.
Radiogenomics is an emerging new field for cancer research. Our results serve as an initial attempt in the radiogenomics of breast cancer and provide guidance for future investigations. We did not investigate the relationship between radiogenomic features and patient survival since only one mortality event existed among the 91 patients. The power of the presented analysis is bounded by the small sample size of 91 patients. As the community starts to accumulate more data, larger studies are expected to shed more light on the relationship between radiogenomic features and clinical outcomes.
Appendix: Information About Genomic Features
1. Gene expression (GE) is the process in which the genetic information (DNA code) of a gene is transcripted into a messenger RNA (mRNA), which further serves as a template used in the synthesis of a functional gene product. Usually, the functional gene product is a protein for protein coding genes. GE in our analysis refers to the level of gene expression, which is the quantity of mRNAs that is transcripted from a gene.
2. Copy number (CN) in our analysis refers to the number of copies of a gene in the genome. In cancer, the CN of a gene may change, which is called CN variation. It is a form of genetic structural variation of DNA CN, GE  CDKN1B  CN, GE   MAP2K4  CN, GE  TBX3  CN, GE   PAK1  CN, GE  TBX4  CN, GE   RSF1  CN, GE  TBX5  CN, GE   AURKB  CN, GE  CTCF  CN, GE   BCL2  CN, GE  FOXA1  CN, GE   BUB1  CN, GE  RUNX1  CN, GE   CDCA3  CN, GE  CBFB  CN, GE   CDCA4  CN, GE  AFF2  CN, GE, ME   CDC20  CN, GE  PIK3R1  CN, GE   CDC45  CN, GE  PTPN22  CN, GE   CHEK1  CN, GE  PTPRD  CN, GE   FOXM1  CN, GE  NF1  CN, GE   HDAC2  CN, GE  SF3B1  CN, GE   IGF1R  CN, GE  CCND3  CN, GE   KIF2C  CN, GE  ATM  CN, GE, ME   KIFC1  CN, GE  BRCA1  CN, GE   MTHFD1L  CN, GE  BRCA2  CN, GE   RAD51AP1  CN, GE  BRIP1  CN, GE   TTK  CN, GE  CHEK2  CN, GE   UBE2C  CN, GE  NBN  CN, GE   ZNF703  CN, GE  RAD51C  CN, GE PTEN CN, GE, ME EGFR CN, GE that results in the change of the number of copies of a gene's DNA segment.
3. DNA methylation (ME) is a biochemical process where a methyl group is added to the cytosine or adenine DNA nucleotides. In adult somatic cells (cells in the body not used for reproduction), ME typically occurs in a CpG dinucleotide context. ME can lead to various effects, such as inhibiting the transcription of genes. In our study, the ME of a gene is the average methylation level of CpG sites that are DNAse hypersensitive and are within 1500 base-pairs upstream of the transcription start site of the gene (see Table 5 ).
mammography and magnetic resonance imaging, understanding the relationship between image-based phenotypes and genomics and their future roles in personalized medicine.
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